1. What is RenMab®, and how does it generate fully human antibodies?
RenMab® is Biocytogen’s fully human monoclonal antibody discovery platform within the RenMice® family. Powered by our proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE™) technology, RenMab® replaces mouse antibody genes with their human counterparts in situ. Natural heavy-light chain pairing and affinity maturation in vivo enable the discovery of diverse high-affinity fully human monoclonal antibodies with favorable developability.
2. Why are fully human antibodies valuable for therapeutic development?
Fully human antibodies can help reduce risk of immunogenicity associated with non-human sequences, including anti-drug antibody (ADA) formation. They also eliminate the need for downstream humanization, providing a direct route to therapeutic candidates while avoiding potential changes in binding or function during humanization.
3. What is the genetic design strategy behind the RenMab® platform?
Unlike random gene insertion approach, RenMab® uses precise in situ gene replacement to replace mouse heavy-chain V(D)J and kappa light-chain variable region loci with their human counterparts, creating a comprehensive human antibody variable-region repertoire. Our platform preserves native regulatory control to support B-cell development, natural antibody gene recombination and immune-driven antibody discovery.
4. What other antibody discovery platforms and formats does Biocytogen offer?
Beyond RenMab® for fully human monoclonal antibody discovery, Biocytogen offers: